Navigation Links
Increased risk for breast cancer death among black women greatest during first 3 years postdiagnosis
Date:10/28/2012

SAN DIEGO Non-Hispanic black women diagnosed with breast cancer, specifically those with estrogen receptor-positive tumors, are at a significantly increased risk for breast cancer death compared with non-Hispanic white women.

"This difference was greatest in the first three years after diagnosis," said Erica Warner, M.P.H., Sc.D., a postdoctoral fellow at Harvard School of Public Health in Boston, Mass., who presented the data at the Fifth AACR Conference on The Science of Cancer Health Disparities, held here Oct. 27-30, 2012.

Prior research has shown that non-Hispanic black women have lower breast cancer survival rates relative to other racial/ethnic groups.

Warner and colleagues conducted a study of 19,480 women who presented to National Comprehensive Cancer Network centers with stage 1 to stage 3 breast cancer between January 2000 and December 2007. They compared breast cancer-specific mortality among 634 Asian women, 1,291 Hispanic women, 1,500 non-Hispanic black women and 16,055 non-Hispanic white women.

After a median follow-up of 6.9 years, the researchers found that non-Hispanic black women had a 48 percent higher risk for breast cancer death in the first three years after diagnosis compared with non-Hispanic white women. After three years, non-Hispanic black women had a 34 percent increased risk for breast cancer-specific mortality.

"The higher risk for early death among black women was more striking among women with estrogen receptor-positive tumors," Warner said.

Non-Hispanic black women with estrogen receptor-positive tumors were more than twice as likely to die from breast cancer within the first three years of diagnosis compared with non-Hispanic white women. This risk was also increased in non-Hispanic black women with luminal A and luminal B breast cancer subtypes.

"This finding is important because these are the types of tumors that we traditionally think of as more treatable," Warner said.

No difference in breast cancer mortality between non-Hispanic black and white women was found for estrogen receptor-negative, basal or HER2-overexpressing tumor subtypes.

Warner and colleagues also evaluated breast cancer survival among Asian and Hispanic women. Compared with non-Hispanic white women, data indicated that Asian women had a 40 percent lower risk for breast cancer death. The researchers observed this decreased risk in all breast cancers and in estrogen receptor-negative, luminal A and HER2-overexpressing tumors. They found no significant differences between non-Hispanic white women and Hispanic women for breast cancer mortality.

"The results of this study emphasize that clinical management and follow-up for patients with breast cancer, particularly black women, is important in the first few years after diagnosis," Warner said. "Although the difference between blacks and whites was highest for this time period, the risk for death was highest in the first few years after diagnosis for all groups."


'/>"/>
Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. High-risk carotid artery plaque formation is increased in older COPD patients
2. Foot Ulcers Tied to Increased Death Risk for People With Diabetes
3. Steroid injection linked to increased risk of bone fractures
4. Experts call for increased neonatal inclusion in pediatric drug trials
5. Early menopause associated with increased risk of heart disease, stroke
6. Substance-use disorders linked to increased risk of death for veterans with PTSD
7. No increased risk of cancer for people with shingles
8. Shingles Not Linked to Increased Cancer Risk, Study States
9. Attractive names sustain increased vegetable intake in schools
10. Increased dietary fructose linked to elevated uric acid levels and lower liver energy stores
11. Low ghrelin - Reducing appetite at the cost of increased stress?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... ... 2017 , ... The Centers for Advanced Orthopaedics (The Centers), ... Robinson as chief operating officer (COO). In this role, Robinson brings more than ... of simplifying business processes and developing growth strategies to increase market share. ...
(Date:6/26/2017)... RU (PRWEB) , ... June 26, 2017 , ... ... released a whitepaper that pledges to solve many catastrophic issues within funding campaigns. ... 2017. , The typical notion of crowdfunding - the raising of funds through the ...
(Date:6/25/2017)... ... 25, 2017 , ... An increase in wetter weather in the Northern California ... with that; a humdinger of an allergy season. A relief from drought conditions is ... misery-causing grass and weed pollen. , “Our patients have been reporting the typical ...
(Date:6/24/2017)... PA (PRWEB) , ... June 24, 2017 , ... ... held in Erie, PA at the Sheraton Erie Bayfront and Erie Convention Center ... evidence based medicine experience, exhibits, a student quiz bowl, award and scholarship presentations, ...
(Date:6/23/2017)... Alexandria, VA (PRWEB) , ... June 23, 2017 ... ... short of what is needed and will ultimately do significant harm to people ... care to everyone. , "While it leaves in place the Affordable Care ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... , June 9, 2017 AirXpanders, Inc. (ASX: ... on the design, manufacture, sale and distribution of the ... the progress of its commercial roll-out in ... in more than one hundred (100) medical institutions and ... AeroForm offers a needle-free alternative for women who choose ...
(Date:6/7/2017)... DUBLIN , June 7, 2017 Endo ... on June 7, 2017, the Hon. Joseph R. ... District of West Virginia , entered ... Systems, Inc. Pelvic Repair System Products Liability Litigation (the ... filed MDL cases to provide expert disclosures on specific ...
(Date:6/3/2017)... 2017  Eli Lilly and Company (NYSE: ... the Phase 3 MONARCH 2 study showed that ... in combination with fulvestrant, significantly improved progression-free survival ... women with hormone-receptor-positive (HR+), human epidermal growth factor ... relapsed or progressed after endocrine therapy (median PFS, ...
Breaking Medicine Technology: